"Evidence shows iodine deficiency greatly impacts breast pain and studies show much higher doses reduce pain."
In 2 Studies we will looking at iodine's impact on disease and health. What may surprise you is the massive doses they were taking in comparison to the RDA of 150 μg/day.
The median intake of iodine from food in the United States is approximately 240 to 300 μg/day for men and 190 to 210 μg/day for women.
The Tolerable Upper Intake Level for adults is 1,100 μg/day (1.1 mg/day).
SO WHY ARE SUCH LARGE DOSES USED FOR
Here are a few notes in case it's a little complicated.
"All doses were associated with an acceptable safety profile. No dose-related increase in any adverse event was observed. "
Strange since there is such fear with high doses after all the Tolerable Upper Intake Level for adults in the US is 1100 μg/day according to a study by The Institute of Medicine (US) Panel on Micronutrients. Washington (DC): National Academies Press (US); 2001.
I think this is because of the chemistry of Florine, Clorine, and Bomine being used by the thyroid in the absence of Iodine.
Abstract: A randomized, double-blind, placebo-controlled, multicenter clinical trial was conducted with 111 otherwise healthy euthyroid women with a history of breast pain. Patients had to document moderate or severe breast pain by recording a score ≥5 on a visual analog scale (VAS) of pain for ≥6 days per cycle and had to present with fibrosis involving at least 25% of both breast surfaces. Subjects could not be effectively treated with more conservative measures such as local heat or nonprescription analgesics. There was not a statistically significant difference in the dropout rate for patients on placebo (11.8%), 1.5 mg/day (31.3%), 3.0 mg/day (18.4%), or 6.0 mg/day (25%) of molecular iodine for 6 months. Physicians assessed breast pain, tenderness, and nodularity each cycle; patients assessed breast pain and tenderness with the Lewin breast pain scale at 3-month intervals and with a VAS at each cycle. A statistically significant improvement (p < 0.01) associated with dose was observed in the Lewin overall pain scale for all treated groups compared to placebo. Reductions in all three physician assessments were observed in patients after 5 months of therapy in the 3.0 mg/day (7/28; 25%) and 6.0 mg/day (15/27; 18.5%) treatment groups, but not the 1.5 mg/day or placebo group. Patients recorded statistically significant decreases in pain by month 3 in the 3.0 and 6.0 mg/day treatment groups, but not the 1.5 mg/day or placebo group; more than 50% of the 6.0 mg/day treatment group recorded a clinically significant reduction in overall pain. All doses were associated with an acceptable safety profile. No dose-related increase in any adverse event was observed.
Kessler PhD First published: 5 July 2004
David Brownstein MD reports three cases of spontaneous regression of breast cancer after women take iodine supplementation.
Iodine, Why You Need It , Why You Can’t Live Without It, by David Brownstein MD
Fourth Edition 2009, Medical Alternatives Press. (This is reported on page 63 of the Iodine Book by David Brownstein MD.)